Year |
Citation |
Score |
2020 |
Shingleton J, Wang J, Baloh C, Dave T, Davis N, Happ L, Jadi O, Kositsky R, Li X, Love C, Panea R, Qin Q, Reddy A, Singhi N, Smith E, et al. Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells. Cold Spring Harbor Perspectives in Medicine. PMID 32152246 DOI: 10.1101/Cshperspect.A034843 |
0.304 |
|
2020 |
Reddy A, Flemming D, Selitsky S, Pavel AB, Alexe G, Bhanot G. Abstract 858: PrismML: A machine learning platform to query genotype-phenotype patterns in large genomics studies Cancer Research. 80: 858-858. DOI: 10.1158/1538-7445.Am2020-858 |
0.304 |
|
2019 |
Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, Otieno JA, Ong'echa JM, Oduor CI, Schroeder KMS, Masalu N, Chao NJ, Agajanian M, Major MB, Fedoriw Y, et al. The whole genome landscape of Burkitt lymphoma subtypes. Blood. PMID 31558468 DOI: 10.1182/Blood.2019001880 |
0.346 |
|
2019 |
Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Reddy A, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3 |
0.382 |
|
2018 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. PMID 30559381 DOI: 10.1038/S41586-018-0722-X |
0.332 |
|
2018 |
Van Mater D, Xu E, Reddy A, Añó L, Sachdeva M, Huang W, Williams N, Ma Y, Love C, Happ L, Dave S, Kirsch DG. Injury promotes sarcoma development in a genetically and temporally restricted manner. Jci Insight. 3. PMID 30333301 DOI: 10.1172/Jci.Insight.123687 |
0.301 |
|
2018 |
Davis N, McKinney MS, Reddy A, Love C, Smith E, Happ L, Dave S. Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma Blood. 132: 1370-1370. DOI: 10.1182/Blood-2018-99-119639 |
0.344 |
|
2018 |
Huang J, Chen M, Whitley MJ, Kuo H, Xu ES, Walens A, Mowery YM, Mater DV, Eward WC, Cardona DM, Luo L, Ma Y, Lopez OM, Nelson CE, Robinson-Hamm JN, ... Reddy A, et al. Abstract A17: Generation and comparison of CRISPR/Cas9 and Cre-mediated genetically engineered mouse models of sarcoma Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-A17 |
0.354 |
|
2017 |
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 171: 481-494.e15. PMID 28985567 DOI: 10.1016/J.Cell.2017.09.027 |
0.356 |
|
2017 |
Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, ... ... Reddy A, et al. Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets. Blood. PMID 28801451 DOI: 10.1182/Blood-2017-02-767335 |
0.347 |
|
2017 |
Huang J, Chen M, Whitley MJ, Kuo HC, Xu ES, Walens A, Mowery YM, Van Mater D, Eward WC, Cardona DM, Luo L, Ma Y, Lopez OM, Nelson CE, Robinson-Hamm JN, ... Reddy A, et al. Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nature Communications. 8: 15999. PMID 28691711 DOI: 10.1038/Ncomms15999 |
0.307 |
|
2017 |
Li J, Roy S, Kim YM, Li S, Zhang B, Love C, Reddy A, Rajagopalan D, Dave S, Diehl AM, Zhuang Y. Id2 Collaborates with Id3 To Suppress Invariant NKT and Innate-like Tumors. Journal of Immunology (Baltimore, Md. : 1950). PMID 28258199 DOI: 10.4049/Jimmunol.1601935 |
0.356 |
|
2017 |
McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, ... ... Reddy A, et al. The Genetic Basis of Hepatosplenic T Cell Lymphoma. Cancer Discovery. PMID 28122867 DOI: 10.1158/2159-8290.Cd-16-0330 |
0.356 |
|
2017 |
Zhang J, Reddy A, Davis N, Moffitt A, Love C, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg M, Norgaard PH, Pedersen MØ, Gang AO, Hogdall E, Heavican T, et al. Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa Blood. 130: 37-37. DOI: 10.1182/Blood.V130.Suppl_1.37.37 |
0.346 |
|
2016 |
Pavel AB, Sonkin D, Reddy A. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. Bmc Systems Biology. 10: 16. PMID 26864072 DOI: 10.1186/S12918-016-0260-9 |
0.354 |
|
2016 |
Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican TB, Lachel CM, Yu J, Fu K, Ferro RA, Eldorghamy N, Greiner TC, Vose JM, Weisenburger DD, Gascoyne RD, ... ... Reddy A, et al. Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target Blood. 128: 4095-4095. DOI: 10.1182/Blood.V128.22.4095.4095 |
0.334 |
|
2016 |
Zhang J, Reddy A, Love C, Moffitt AB, Rajagopalan D, Leppä S, Pasanen A, Meriranta L, Karjalainen-Lindsberg M, Norgaard PH, Pederson M, Ortved Gang A, Hogdall E, Richards KL, Fedoriw YD, et al. Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups Blood. 128: 1087-1087. DOI: 10.1182/Blood.V128.22.1087.1087 |
0.379 |
|
2015 |
Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, ... ... Reddy A, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Medicine. PMID 26479923 DOI: 10.1038/Nm.3954 |
0.347 |
|
2015 |
Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, et al. Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. Plos One. 10: e0138486. PMID 26378449 DOI: 10.1371/Journal.Pone.0138486 |
0.365 |
|
2015 |
Reddy A, Pinzon-Ortiz M, Derti A, Korn J, Ruddy D, Yang G, Green J, Gao H, Lehar J, Caponigro G, Cao ZA. Abstract 2692: High allele frequency of KRAS functional mutations predicts resistance to MEK inhibitors: Evidence from cell lines and human tumor xenograft models Cancer Research. 75: 2692-2692. DOI: 10.1158/1538-7445.Am2015-2692 |
0.355 |
|
2014 |
Wang K, Shrestha R, Wyatt AW, Reddy A, Lehár J, Wang Y, Lapuk A, Collins CC. A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines. Plos One. 9: e103050. PMID 25036042 DOI: 10.1371/Journal.Pone.0103050 |
0.371 |
|
2014 |
Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Molecular Cancer Therapeutics. 13: 1117-29. PMID 24608574 DOI: 10.1158/1535-7163.Mct-13-0865 |
0.38 |
|
2014 |
Lozy F, Cai-McRae X, Teplova I, Price S, Reddy A, Bhanot G, Ganesan S, Vazquez A, Karantza V. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss. Autophagy. 10: 662-76. PMID 24492513 DOI: 10.4161/Auto.27867 |
0.344 |
|
2013 |
Wiesmann M, Stump M, Caponigro G, Duhl D, Firestone B, Gesner T, Gruenenfelder B, Guthy DA, Holash J, King F, Lehar J, Leroy C, Liu M, Petruzelli L, Porter D, ... ... Reddy A, et al. Abstract 2058: Systematic evaluation of drug combinationsin vitroandin vivo. Cancer Research. 73: 2058-2058. DOI: 10.1158/1538-7445.Am2013-2058 |
0.373 |
|
2013 |
Mcsheehy PMJ, Cao A, Caponigro G, Duhl D, Firestone B, Gesner T, Guthy D, Holash J, King F, Lehar J, Leroy C, Liu M, Petruzzelli L, Porter D, Menezes D, ... Reddy A, et al. Abstract A140: Evaluation of prediction of in vivo activity from in vitro combinations: Examples using a MEK1/2 inhibitor combined with docetaxel in NSCLC models. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A140 |
0.358 |
|
2012 |
Nyfeler B, Chen Y, Li X, Pinzon-Ortiz M, Wang Z, Reddy A, Pradhan E, Das R, Lehár J, Schlegel R, Finan PM, Cao ZA, Murphy LO, Huang A. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. Plos One. 7: e48548. PMID 23155392 DOI: 10.1371/Journal.Pone.0048548 |
0.348 |
|
2012 |
Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Plos One. 7: e33788. PMID 22586443 DOI: 10.1371/Journal.Pone.0033788 |
0.402 |
|
2012 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483: 603-7. PMID 22460905 DOI: 10.1038/Nature11003 |
0.403 |
|
2012 |
Huang A, Fritsch C, Wilson C, Reddy A, Liu M, Lehar J, Quadt C, Hofmann F, Schlegel R. Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel Cancer Research. 72: 3749-3749. DOI: 10.1158/1538-7445.Am2012-3749 |
0.391 |
|
2011 |
Liu M, Reddy A, Huang A, Caponigro G, Lehar J. Abstract C70: Integrative analysis of pharmacologic, genomic, and transcriptomic assays in cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-C70 |
0.391 |
|
2011 |
Lozy FJ, Reddy A, Miles G, Bhanot G, Ganesan S, Karantza V. Abstract 3777: Autophagy and HER2 interaction in mammary tumorigenesis Cancer Research. 71: 3777-3777. DOI: 10.1158/1538-7445.Am2011-3777 |
0.388 |
|
2010 |
Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes & Cancer. 1: 152-163. PMID 20871783 DOI: 10.1177/1947601909359929 |
0.361 |
|
2010 |
Venkatesan K, Stransky N, Margolin A, Reddy A, Raman P, Sonkin D, Jones M, Wilson C, Kim S, Warmuth M, Sellers W, Lehar J, Barretina J, Caponigro G, Garraway L, et al. Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-Pr2 |
0.391 |
|
2010 |
Brannon AR, Reddy A, Seiler M, Arreola A, Chen S, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, et al. Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns Cancer Research. 70: 1996-1996. DOI: 10.1158/1538-7445.Am10-1996 |
0.397 |
|
2009 |
Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 137: 1062-75. PMID 19524509 DOI: 10.1016/J.Cell.2009.03.048 |
0.311 |
|
2009 |
Lexe G, Monaco J, Doyle S, Basavanhally A, Reddy A, Seiler M, Ganesan S, Bhanot G, Madabhushi A. Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging. Experimental Biology and Medicine (Maywood, N.J.). 234: 860-79. PMID 19491367 DOI: 10.3181/0902-Mr-89 |
0.339 |
|
2009 |
Reddy A, Ganesan S, Bhanot G. Abstract C37: Ensemble survival prediction for breast cancer using microarray data Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C37 |
0.324 |
|
Show low-probability matches. |